Clinical Trials - November 5, 2014
PMDD Drug Shows Promise
A candidate drug developed by Umecrine Mood AB to treat premenstrual dysphoric disorder (PMDD) showed positive results during a randomized Phase I/II study. Those taking the drug called UC1010 showed a significant reduction in PMDD symptoms compared to those taking a placebo. “UC1010 has been developed specifically to target the atypical effects of progesterone metabolites […]
Clinical Trials - January 8, 2014
Patient recruitment completed in Phase I/II study of Umecrine Mood’s candidate drug
Umecrine Mood AB had announced that patient recruitment for the ongoing phase I/II study with UC1010 for the treatment of severe premenstrual symptoms (PMDD) has been completed. Umecrine Mood is part of the Karolinska Development portfolio. ”About half of the patients planned for the study have completed the treatment. The remaining participants are currently in […]
